New York Eye and Ear Infirmary of Mount Sinai Launches Ophthalmic Innovation and Technology Program
Program Focuses on Breakthrough Surgical Procedures and Development of New Technology
New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the creation of the Ophthalmic Innovation and Technology Program. This academic program is the first of its kind in the New York City metropolitan region.
The program will bring in full-time, world-renowned experts to train faculty and residents in the latest and most advanced surgical technologies in ophthalmology, putting NYEE at the forefront of innovation, establishing a center of excellence, and bringing patients closer to breakthrough technology and minimally invasive surgical techniques.
Mount Sinai doctors will learn how to use new, state-of-the-art devices that make surgeries faster, safer, and more effective for patients. Initially, the training will focus on the latest micro-interventions for glaucoma and cataract procedures, which are transforming clinical care in ophthalmology. The long-term goal is for the program to expand to other areas of minimally invasive ophthalmic surgery.
The Ophthalmic Innovation and Technology Program will use the world-class laboratories, training facilities, and internal talent at NYEE to advance and expand clinical research. Mount Sinai doctors will benefit by getting institutional commitment and resources to create new ideas in surgical technology and develop novel medical products. Additionally, the program will bring more clinical trials to NYEE, giving doctors new access to companies who are investigating novel therapies and surgeries.
“This program will position NYEE to be an international leader in ophthalmic innovation and technology, setting us apart as we strive to develop breakthrough treatments to give patients the best possible outcomes,” said James C. Tsai, MD, MBA, Delafield-Rodgers Professor and System Chair, Department of Ophthalmology, Mount Sinai Health System, and President, NYEE. “This is a novel academic focused platform to foster technological innovation and will hopefully lead to potential commercialization of these technologies.”
Sean Ianchulev, MD, MPH, Professor of Ophthalmology at the Icahn School of Medicine, has been hired by NYEE to serve as the Director of the Ophthalmic Innovation and Technology Program. An internationally recognized innovator, he has pioneered some of the top innovations in ophthalmology over the past decade. As the head of ophthalmology clinical research at Genentech, he led the development of Lucentis, one of the most successful drug therapies in the field, which transformed the treatment of age-related macular degeneration, vein occlusions, and diabetic macular edema. Dr. Ianchulev is also the inventor of intraoperative aberrometry, an advanced technology for intraoperative guidance and precision biometry for cataract surgery that has been used to treat more than 500,000 patients to date. In addition, he led the development of the latest, FDA-approved Microstent Cypass, which is the only supraciliary microstent indicated for intraocular pressure lowering in glaucoma. More recently, he founded the first micro-interventional technology for phaco-less cataract surgery, commercialized by Iantech, Inc.
“I am excited for the opportunity to join the faculty of NYEE and Mount Sinai, where there is so much talent and expertise which can be harnessed to bring clinical excellence and medical innovation synergistically closer to a positive outcome,” said Dr. Ianchulev. “We are in a dynamic age of many developments converging in the field of ophthalmology, particularly micro-interventional technology, which is set to transform everything from glaucoma to cataract treatment. We will start there, raise the sails and capture the momentum of innovation to its fullest.”
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system encompassing (with the addition of South Nassau Communities Hospital) eight hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.